Intellia Therapeutics (NASDAQ:NTLA) CAO Michael Dube Sells 1,871 Shares

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael Dube sold 1,871 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $17.38, for a total value of $32,517.98. Following the transaction, the chief accounting officer directly owned 55,266 shares in the company, valued at approximately $960,523.08. This represents a 3.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Intellia Therapeutics Stock Down 2.3%

NTLA opened at $19.96 on Friday. The business has a 50 day moving average price of $12.88 and a two-hundred day moving average price of $10.32. The company has a market cap of $2.14 billion, a PE ratio of -4.26 and a beta of 2.37. Intellia Therapeutics, Inc. has a 52 week low of $5.90 and a 52 week high of $21.47.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The company had revenue of $14.25 million for the quarter, compared to the consensus estimate of $12.26 million. During the same period last year, the business posted ($1.52) EPS. The company’s revenue was up 104.3% on a year-over-year basis. As a group, sell-side analysts expect that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on NTLA shares. Royal Bank Of Canada cut their price objective on shares of Intellia Therapeutics from $25.00 to $21.00 and set an “outperform” rating for the company in a research report on Friday, August 8th. JMP Securities reissued a “market perform” rating on shares of Intellia Therapeutics in a report on Friday, September 19th. Wedbush restated a “neutral” rating and issued a $7.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Saturday, September 27th. Finally, Wall Street Zen raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 6th. Eleven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Intellia Therapeutics presently has an average rating of “Hold” and a consensus price target of $27.39.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of NTLA. Headlands Technologies LLC purchased a new stake in Intellia Therapeutics in the 2nd quarter worth approximately $26,000. Whipplewood Advisors LLC boosted its holdings in shares of Intellia Therapeutics by 114,900.0% during the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock worth $32,000 after purchasing an additional 3,447 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Intellia Therapeutics by 56.4% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock worth $33,000 after purchasing an additional 1,655 shares during the last quarter. Harbour Investments Inc. grew its position in shares of Intellia Therapeutics by 76.7% in the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company’s stock valued at $37,000 after purchasing an additional 2,264 shares during the period. Finally, Quantbot Technologies LP increased its stake in Intellia Therapeutics by 846.4% in the first quarter. Quantbot Technologies LP now owns 6,663 shares of the company’s stock valued at $47,000 after purchasing an additional 5,959 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.